Atomwise
Robert Mittendorff, MD, MBA, currently serves as General Partner and Head of Healthcare at B Capital Group since March 2021. Mittendorff holds multiple board roles, including positions at Nalu Medical, Inc., Capital Rx, CARRICK THERAPEUTICS UK LIMITED, Carlsmed, Lively, Inc., HotSpot Therapeutics, Inc., and Triumvira Immunologics, Inc. Educational credentials include an MBA from Harvard Business School, an MD from Harvard Medical School, a Master's in International Affairs from King's College London, a high honors B.S. in Biomedical/Electrical Engineering from The Johns Hopkins University, completion of the Emergency Medicine Residency Program at Stanford University School of Medicine, and a graduate program in Systems Engineering/Financial Engineering at the Massachusetts Institute of Technology.
Atomwise
4 followers
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. They've partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.